Compare Stocks → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSEAMERICAN:ARMP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARMPArmata Pharmaceuticals$2.53+1.2%$0.00$1.07▼$5.26$91.46M0.8517,066 shs4,312 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARMPArmata Pharmaceuticals0.00%0.00%0.00%0.00%0.00%World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARMPArmata Pharmaceuticals2.4339 of 5 stars3.55.00.00.00.61.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARMPArmata Pharmaceuticals3.00Buy$7.00176.68% UpsideCurrent Analyst RatingsLatest ARMP and EX1 Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/22/2024ARMPArmata PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARMPArmata Pharmaceuticals$4.53M20.19N/AN/A($0.89) per share-2.84Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARMPArmata Pharmaceuticals-$69.04M-$1.98N/AN/AN/A-1,524.51%-280.95%-52.61%5/9/2024 (Estimated)Latest ARMP and EX1 EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023ARMPArmata PharmaceuticalsN/A-$0.55-$0.55-$0.55$0.68 million$1.53 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARMPArmata PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARMPArmata PharmaceuticalsN/A1.161.16OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARMPArmata Pharmaceuticals3.57%Insider OwnershipCompanyInsider OwnershipARMPArmata Pharmaceuticals85.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableARMPArmata Pharmaceuticals6636.15 million5.24 millionNot OptionableARMP and EX1 HeadlinesSourceHeadlineArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Updateamericanbankingnews.com - April 16 at 5:58 AMArmata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading Down 1.8%marketbeat.com - April 13 at 12:40 AMBuy Rating Affirmed for Armata Pharmaceuticals Amid Progress in Bacteriophage Therapy Developmentmarkets.businessinsider.com - March 25 at 9:35 PMArmata Pharmaceuticals Inc (ARMP) Earnings: Navigates Through R&D to Narrow Lossesfinance.yahoo.com - March 23 at 6:02 AMBuy Rating Affirmed for Armata Pharmaceuticals Amid Clinical Progress and Strategic Growthmarkets.businessinsider.com - March 22 at 6:26 PMArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Updatefinanznachrichten.de - March 22 at 8:33 AMArmata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Updatefinance.yahoo.com - March 21 at 5:31 PMINVA Apr 2024 15.000 callfinance.yahoo.com - March 15 at 9:13 PMINVA Mar 2024 7.500 callfinance.yahoo.com - March 10 at 5:07 PMArmata secures $35 million to fund phage therapy trialsinvesting.com - March 6 at 4:20 PMArmata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innovivafinance.yahoo.com - March 4 at 4:17 PMArmata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summitfinance.yahoo.com - February 21 at 8:42 AMArmata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summitprnewswire.com - February 21 at 7:00 AMArmata Pharmaceuticals Inc (ARMP)investing.com - February 10 at 5:30 PMArmata Pharmaceuticals Inc ARMPmorningstar.com - February 2 at 10:01 PMRobust Advancements and Strategic Planning: Key Drivers for Armata Pharmaceuticals’ Buy Ratingmarkets.businessinsider.com - November 15 at 11:46 PMArmata Pharmaceuticals Inc (ARMP) Reports Q3 2023 Financial Results and Corporate Updatesfinance.yahoo.com - November 15 at 1:46 PMArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Updatefinanznachrichten.de - November 15 at 8:45 AMArmata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Updatefinance.yahoo.com - November 14 at 7:41 PMLexeo Therapeutics Inc.money.usnews.com - November 6 at 10:49 PMArmata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conferencefinance.yahoo.com - October 30 at 9:28 AMArmata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023finance.yahoo.com - October 19 at 8:55 AMArmata Pharmaceuticals (ARMP) Price Target Increased by 14.29% to 8.16msn.com - October 4 at 10:01 PMArmata Pharmaceuticals: Promising Clinical Trials and New Leadership Bolster Buy Recommendationmarkets.businessinsider.com - September 28 at 7:47 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsArmata PharmaceuticalsNYSEAMERICAN:ARMPArmata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
